Notoginsenoside Ft
1 is a saponin originally isolated from
P. notoginseng with diverse biological activities.
1,2,3,4,5 It induces proliferation, migration, and tube formation of human umbilical vein endothelial cells (HUVECs)
via nuclear translocation of hypoxia-inducible factor-1α (HIF-1α) and activation of the PI3K/AKT and Raf/MEK/ERK signaling pathways in a manner dependent on mammalian target of rapamycin (mTOR).
1 Notoginsenoside Ft
1 (45 μM) induces cell cycle arrest at the S and G
2/M phases and promotes apoptosis of SH-SY5Y cells.
2 It increases cGMP levels and induces relaxation of isolated precontracted rat mesenteric arteries, effects that are reversed by the nitric oxide synthase inhibitor L-NAME (Item No.
80210) and ODQ (Item No.
81410), an inhibitor of soluble guanylyl cyclase.
3 In vivo, notoginsenoside Ft
1 (0.25, 2.5, and 25 mg/kg) promotes angiogenesis and decreases wound diameter in a mouse model of punched-hole ear injury.
1 Notoginsenoside Ft
1 (1.25 mg/kg) decreases tail bleeding time and increases thrombus weight in a rat tail bleeding assay.
4 Topical administration of notoginsenoside Ft
1 increases mRNA expression of the collagen expression, fibroblast proliferation, and scar formation genes COL1A1, COL3A1, TGF-β1, TGF-β3, and fibronectin, promotes neovascularization, reduces monocyte infiltration, and shortens wound closure time in a
db/db mouse model of diabetic foot ulcers.
5 
